Effect of cyclic estrone sulfate treatment on lipid profiles of postmenopausal women with elevated cholesterol levels

Article Abstract:

Heart disease is a leading cause of death among menopausal women. During menopause the ovaries stop making the hormone estrogen, which is thought to protect women from coronary heart disease by preventing changes in blood lipids (fats) by increasing the ratio of high-density lipoprotein (HDL) to low-density lipoprotein (LDL) cholesterol. In an effort to lower the risk of heart disease, estrogen replacement therapy is offered to menopausal women. How estrogen (or the lack of estrogen) affects the lipid profile of menopausal women is unclear. This study was conducted to compare the effects of two different cyclic doses of estrogen on the lipid profile of menopausal women who had high blood cholesterol (219 milligrams per deciliter and above) at the onset. Menopausal women were given estrone sulfate 0.625 milligrams (59 women), estrone sulfate 1.25 mg (43 women ) or a placebo (51 women) for the first 25 days of each of 12 months followed each time by a medication-free withdrawal period from day 26 to day 31. The average total cholesterol level was 262 mg per dL for the women receiving 0.625 mg, 269 for the women receiving 1.25 mg and 262 for the women who received the placebo. The amount of HDL, LDL and the ratio of HDL to LDL were measured after six, nine and 12 months of treatment. The trend towards a increase in HDL, decrease in LDL and a rise in the ratio of HDL to LDL depended on the dose of estrogen taken. These results support a dose-response relationship between the concentration of estrone sulfate. Estrone produced a favorable lipid profile by raising HDLs and lowering LDLs in menopausal women with high baseline total blood cholesterol. (Consumer Summary produced by Reliance Medical Information, Inc.)

Health aspects, Risk factors, Dosage and administration, Postmenopausal women, Hypercholesterolemia, Estrone

---

Effect on plasma lipids and lipoproteins of postmenopausal oestrogen therapy with added dydrogesterone

Article Abstract:

The effect of adding the progestogen dydrogesterone to 1.25 milligrams (mg) daily of horse-derived estrogen for treating symptoms of menopause was assessed. Specifically, the effects of this combined drug regimen on blood lipids and lipoproteins were examined in 14 postmenopausal women. Seven of these women received 20 mg dydrogesterone daily for 12 days during months two, three, and four; followed by 10 mg daily for months five, six, and seven. The sequence of dydrogesterone doses was reversed in the remaining seven women. Dydrogesterone was not given to the women during months eight and nine. The results were compared with those of eight untreated postmenopausal women. The blood levels of high density lipoprotein (HDL)-2-cholesterol and HDL-3-cholesterol were significantly altered in untreated women. Postmenopausal women who received combined hormone therapy had higher HDL-cholesterol and apolipoprotein (apo) A1 and lower low density lipoprotein (LDL)-cholesterol and apo B levels compared with those in untreated women at months four, seven, and nine. Although hormone treatment increased triglyceride levels, these levels were still within normal range. The changes in blood lipids and lipoproteins were similar for the different doses of dydrogesterone and during treatment phases with and without dydrogesterone. These findings suggest that the addition of dydrogesterone does not cause significant adverse changes in blood lipids and lipoproteins. (Consumer Summary produced by Reliance Medical Information, Inc.)

Analysis, Lipoproteins, Blood lipoproteins, Dydrogesterone

---

Long-term effects of hormone replacement therapy on the uterus and on uterine circulation

Article Abstract:

Long-term hormone replacement therapy may cause abnormalities in the uterus or uterine circulation. Postmenopausal women may undergo hormone replacement therapy to alleviate the symptoms of menopause and to prevent osteoporosis or cardiovascular disorders. Among 432 women between 58 and 59 years old who underwent Doppler ultrasound to measure the size of their uterus and to evaluate uterine blood flow, 271 were not receiving hormone replacement, 143 were receiving hormone replacement therapy and 18 had discontinued hormone replacement therapy. The average size of the uterus was larger in women undergoing hormone replacement therapy than in women not undergoing hormone replacement therapy. The lining of the uterus was thicker and uterine blood flow was different in women receiving hormone replacement therapy than in those not receiving hormone replacement therapy or who had discontinued hormone replacement therapy.

Uterus, Uterine circulation

Similar abstracts:

• Abstracts: Effect of salt restriction on urine hydroxyproline excretion in postmenopausal women. Treatment of postmenopausal hyperparathyroidism with norethindrone
• Abstracts: Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test
• Abstracts: Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months. part 2 Overview of the HCFA study of cost and utilization of AIDS services in California and New York
• Abstracts: Efficacy of single-dose versus seven-day trimethoprim treatment of cystitis in women: a randomized double-blind study
• Abstracts: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.